FOSL2

Across TCGA pan-cancer cohorts, FOSL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FOSL2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FOSL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FOSL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where FOSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.490	0.870	.003	45	view →
GBM	DFS	Tertile	All	0.230	0.471	.001	20	view →
HNSC	OS	Median	IV	0.745	0.927	.022	9	view →
PDAC	DFS	Quartile	III,IV	0.173	0.884	.006	7	view →
LSCC	DFS	Median	All	0.979	0.893	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FOSL2–CCRCC (OS)

Open the CCRCC breakdown →